Our Expert Network

  1. Beyond Hairpins: A New Translational Repression Assay Expands RNA-Binding Protein Research 5/26/2026

    Researchers expanded translational repression assays beyond RNA hairpins, enabling scalable study of linear RNA-protein interactions in living cells.

  2. Engineering RNA Payload Distribution In LNPs To Unlock Higher In Vivo Gene Editing Efficiency 5/22/2026

    New research shows RNA payload distribution inside LNPs — not just encapsulation efficiency — may be key to unlocking stronger in vivo gene editing performance.

  3. Beyond Guanidine: Scientists Discover A Mysterious Riboswitch Variant With A Different Biological Target 5/22/2026

    Scientists identified a mysterious riboswitch variant that resembles guanidine sensors but likely evolved to detect an entirely different metabolite.

  4. RNA Modification-Mediated Translational Control In Immune Cells 5/20/2026

    Exploring how m6A RNA modifications control immune cell translation, influencing inflammation, tumor immunity, T cell activation, and future immunotherapies.

  5. Repeating Sanofi's Ballroom Design On Two Continents 5/15/2026

    Moveable walls and a stunning number of robotics at its sites in France and Singapore, among other features, has earned Sanofi international recognition for innovation.

  6. Validation Of A RIG-I–Based Functional Assay For Quantitative Detection Of Double-Stranded RNA Impurities In mRNA Drug Substance 5/13/2026

    A validated RIG-I assay adds a biology-informed layer to dsRNA testing by quantifying immunogenic impurities in IVT-derived mRNA therapeutics for deeper functional insight.

  7. Suppressor tRNA Therapeutics: A New Frontier In Treating Genetic Disease 5/8/2026

    Suppressor tRNAs could unlock a scalable new way to treat genetic diseases caused by nonsense mutations, restoring full-length proteins across multiple indications.

  8. Engineering Transient In Vivo CAR-T: Extending Expression, Expanding Access, And Rethinking Immune Reset 5/4/2026

    In this Q&A, Michael Lam, Ph.D., explores how circular RNA and targeted delivery extend transient CAR expression to enable deep B-cell depletion and controllable immune reset.

  9. Engineering Repeat-Dose RNA: Engineering Around Immune Recognition In Repeat-Dose RNA Therapeutics 4/30/2026

    Designing repeat-dose RNA means engineering around immune recognition — optimizing payloads, purity, and delivery early to sustain efficacy, tolerability, and durability across multiple administrations.

  10. Bridging The Manufacturing Chemistries Between Drug Research And Development For Morpholino Oligos 4/29/2026

    Standardizing Morpholino chemistry could streamline development and FDA pathways, improving consistency, scalability, and delivery performance across antisense therapeutics.